NCT02493582 2016-02-05The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFRThe First People's Hospital of ChangzhouPhase 2 Active not recruiting400 enrolled